柯俊良Jiunn-Liang Ko王秉彥Bing-Yen Wang醫學研究所2026-10-299999-12-312015https://handle.ncl.edu.tw/11296/2482ephttps://scholars.csmu.edu.tw/handle/123456789/36116肺癌是仍然所有癌症中主要的死因,而新版的肺癌的分期於2007年更新,其中分期主要的依據為TNM系統,也就是腫瘤大小(T),淋巴結轉移程度(N)和是否有遠端轉移(M)。然而許多臨床因子也可能預測肺癌病人的預後,卻沒有在新版的TNM系統被陳述,所以本研究利用台灣健保資料庫從2002年到2008年,總共有43986病人被診斷為肺癌,其中因為10067位病人資料不完全而被排除,最後有33919位病人納入本研究,來探討肺癌病人臨床病理預後因子。接近3分之2的病人為男性,所有33919位病人之中,5年的存活率為15.9%,存活的中位時間為13.2個月。病人被診斷為臨床1期有4254人(12.5%)、臨床2期有1140人(3.4%)、臨床3期有10161人(30.0%)、臨床4期有18364人。在多變項分析之中,年紀大於65歲、性別、組織型態、腫瘤位置皆為獨立的預後因子。大於65歲被診斷肺癌有較差的預後,台灣男性比女性有較差的預後、扁平麟狀上皮癌較腺癌有較差的存活,細胞分化越差預後越差,腫瘤生長在下肺葉比上肺葉有較差的預後,有接受手術預後較佳,其中又以肺葉切除手術效果最佳。根據本大型人口學的研究,除了傳統的TNM系統之外,可以考慮加入以上的臨床因素作為肺癌分期的參考。肺癌的成因十分複雜,臨床亦發現肺癌病例有高達90%和抽菸有關。Benzo[a]pyrene (B[a]P),屬於Polycyclic aromatic hydrocarbons (PAHs)是存在於香菸及環境中的一種致肺癌物質。我們研究在於探討B[a]P對肺癌細胞株H1355造成細胞S週期停滯的分子機制,以BrdU流式細胞實驗發現ERK抑制劑PD98059會抑制B[a]P造成S週期停滯的現象,此外採用VSV-G pseudotyped lentivirus –shRNA抑制MAPK1 (ERK2)的表現,發現B[a]P所誘發Chk1活化也受到抑制,因此ERK活化和下游的Chk1可能參與在B[a]P誘導H1355細胞S期累積。我們還發現,B[a]P沒有誘導和細胞自噬有關的蛋白LC3轉換而且溶酶體抑制劑chloroquine對B[a]P誘導S相積累並沒有影響。此外,組蛋白去乙醯化酶(Histone deacetylases, HDAC)抑製劑chidamide會回復B [a]所誘導S期的積累和抑制ERK的磷酸化。結果顯示,B[a]P會經由活化ERK再造成下游Chk1活化而誘導細胞S期積累,因此抑制ERK、Chk1的磷酸化和HDAC抑制劑可能在肺癌治療上具有發展的潛力。Lung cancer is the leading cause of cancer death in Taiwan. This study investigated the prognostic factors affecting survival of patients with lung cancer in Taiwan. Data were obtained from the National Health Insurance Research Database (NHIRD) published in Taiwan. Clinicopathologic profiles and prognostic factors of 33,919 lung cancer patients were analyzed between 2002 and 2008 in this retrospective review. The impact of the clinicopathologic factors on overall survival was assessed. Nearly two-thirds of the patients were men. The 5-year survival rate was 15.9%, with a median survival of 13.2 months. The clinical staging of the patients included stage I (n=4,254; 12.5%), stage II (n=1,140; 3.4%), stage III (n=10,161; 30.0%), and stage IV (n=18,364; 54.1%). In the multivariate analysis, age >65 years, sex, cell type, histologic grade, and primary tumor location were identified as independent prognostic factors. In additional to tumor-nodes-metastasis (TNM) staging system, patient sex and age, tumor location, cell type, and differentiation were independent prognostic factors. We recommend incorporation of these factors in order to sub-classify lung cancer patients. Benzo[a]pyrene (B[a]P), the most extensively evaluated polycyclic aromatic hydrocarbons (PAHs) has a potent lung carcinogenic activity derived from tobacco smoking and environmental contamination. An approximately 90% correlation between smoking and lung cancer incidence. This study aimed to investigate the molecular mechanisms responsible for B[a]P-induced cell cycle S-phase accumulation in H1355 non-small cell lung cancer (NSCLC) cell . We found that ERK activity inhibitor PD98059 inhibited B[a]P-induced S-phase accumulation in H1355 using BrdU flow cytometry. In addition, using VSV-G pseudotyped lentivirus –shRNA for MAPK1 (ERK2) silence, checkpoint kinase-1 (Chk1)-phosphorylation induced by B[a]P was abolished. These results suggested that ERK activation and downstream mediator Chk1 may contribute to B[a]P-induced S phase accumulation in H1355 cells. We also found that B[a]P did not induce LC3 conversion and lysosome inhibitor chloroquine (CQ) had no effect on B[a]P-induced S-phase accumulation. Furthermore, histone deacetylases (HDAC) inhibitor chidamide reversed the B[a]P-induced S phase accumulation and blocked ERK phosphorylation. This results indicate that B[a]P induces S phase accumulation via ERK-mediated Chk1 activation. Inhibition of ERK-mediated Chk1 phosphorylation and HDAC inhibitor may be potential in lung cancer therapy development.肺癌苯並芘細胞週期停滯Lung cancerBenzo[a]pyreneCell cycle arrest探討肺癌的臨床預後因子及Benzo[a]pyrene影響肺癌細胞週期停滯thesis